"Avoidable Deaths" - Union for International Cancer Control

Union for International Cancer Control

"Back to Basics: The Concept of HRQL Under a Magnifying Glass" - EORTC Quality of Life Group

EORTC Quality of Life Group

"Bald for a Cause" initiative - UWC Dilijan College

"Bald for a Cause" initiative - UWC Dilijan College

Emily Drake: I’m starting a new position at McGill Faculty of Medicine and Health Sciences

Emily Drake, Social Media Tips

Ben Derman: Some thoughts on Elrantamab in light of approval.

Ben Derman: Some thoughts on Elrantamab in light of approval.

National Cancer Institute of Kenya - 30 Days Left Until the 2nd National Cancer Summit

National Cancer Institute of Kenya

What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC

NSCLC

Sumanta K. Pal: The picture of our illustrious team

Sumanta K. Pal

Arndt Vogel: Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.

Arndt Vogel: Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.

immunotherapy

Patrick Soon-Shiong

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Patrick Soon-Shiong
Dana Dornsife

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding
Matt Sherer

Matt Sherer: ASCO Supports Permanent Medicare Telehealth
FDA PreCheck

New FDA PreCheck Program to Boost U.S. Drug Manufacturing